Results from the LEADERS FREE trial found that a polymer-free drug-coated stent (DCS) was superior to a bare-metal stent (BMS) in high-bleeding-risk patients treated with one month of dual antiplatelet therapy (DAPT). It was the first randomized clinical trial dedicated to this particular patient population.

ISAR-DESIRE 4 trial, TCT 2015, drug-coated balloon, DCB, scoring balloon, SCB, drug-eluting stent restenosis

Results from the ISAR-DESIRE 4 trial indicate that use of a scoring balloon plus a paclitaxel-coated balloon (PCB) was angiographically superior to a paclitaxel-coated balloon alone for the treatment of restenosis within limus-eluting stents.

Direct Flow Medical Inc. announced one-year outcomes from the DISCOVER post-market study that demonstrate excellent real-world results for the Direct Flow Medical Transcatheter Aortic Valve System. The data were presented last week at the Transcatheter Cardiovascular Therapeutics (TCT) annual meeting by Federico De Marco, M.D., from the Policlinico San Donato in Milan, Italy.

PulsePoint Respond app, new CPR guidelines, sudden cardiac arrest, social media
Physio-Control, PulsePoint Respond app, new CPR guidelines, social media

For the first time, cardiopulmonary resuscitation (CPR) guidelines issued by the American Heart Association (AHA) recommend communities consider using social media and mobile app technology to alert CPR responders when someone nearby suffers sudden cardiac arrest. The new guidelines cite studies that show emerging mobile technologies can result in a “higher rate of bystander-initiated CPR.”

Bracco Diagnostics Inc. announced that Lumason was approved by the Centers for Medicare and Medicaid Services (CMS) for pass-through status under the Hospital Outpatient Prospective Payment System (HOPPS). Lumason is an ultrasound contrast agent indicated for use in adults with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border.

thrombus aspiration, STEMI patients, TCT 2015, TOTAL study

A pair of studies presented at the 27th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium showed no late benefit of thrombus aspiration during percutaneous coronary intervention (PCI) in patients with ST-segment elevation myocardial infarction (STEMI).
BRAVO 3 trial results, bivalirudin, heparin, anticoagulation, TAVR, TCT 2015

Results from the BRAVO 3 trial found that bivalirudin did not significantly reduce major bleeding rates at 48 hours or adverse events at 30 days compared to heparin in high-risk patients undergoing transcatheter aortic valve replacement (TAVR).

October 19, 2015 — Vascular Interventional Advances (VIVA) Physicians, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and research, announced the late-breaking sessions at its annual conference, VIVA 2015. Sixteen trial results, featuring the latest in vascular technology and devices, will be released for the first time Nov. 2-3 at the Wynn Las Vegas.

The U.S. Food and Drug Administration (FDA) granted accelerated approval to Praxbind (idarucizumab) for use in patients who are taking the anticoagulant Pradaxa (dabigatran) during emergency situations when there is a need to reverse Pradaxa’s blood-thinning effects.

Amaranth Fortitute Bioresorbable stent

There were several overarching technology trends seen at the 2015 Transcatheter Cardiovascular Therapeutics (TCT) annual meeting in San Francisco Oct. 11-15. The key technologies emphasized this year included new transcatheter devices in development to treat not only the aortic valve, but also the mitral and tricuspid valves. Bioresorbable stents and bioresorbable drug carrier polymers for metallic stents were heavily highlighted in sessions and on the show floor. Several TCT sessions also centered on the new economic realities hospitals face with pressures of healthcare reform. 
Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now